Cathy Burgess, a Health Care Group partner in the firm’s Washington, D.C. office, was quoted in an article discussing the proposed language redefining current good manufacturing practices (cGMP) included in both versions of omnibus FDA user fee legislation.
The full article sharing Burgess’ insights can be viewed here.